Crystalloid
PreclinicalSmall molecule
Crystalloid is one of 90 small molecule programs targeting Hemodynamic. It is currently in Preclinical.
4
Indications
14
Total Trials
0
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
92 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Osmitrol
BB. Braun Medical Inc.
Approved
Giapreza
LLa Jolla Pharmaceutical Company
Phase 3
Oraverse
LLife Extension Foundation Inc.
Phase 3
Lamisil
NovartisPhase 2
Northera
LundbeckPhase 2
Desferal
Jazz PharmaceuticalsPhase 2
Pitressin
AAultman Health Foundation
Phase 2
Arginine Vasopressin
SStanford University
Phase 3
Jardiance
Boehringer IngelheimPhase 1
IRBESARTAN,
AAssistance Publique - Hôpitaux de Paris
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fluid Resuscitation4 trials
Hypotension2 trials
5 more indications
Postoperative Morbidity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Crystalloid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKonkuk University Medical Center